Gilles BESIN

Gilles Besin has a diverse work experience in the field of scientific research and development. Gilles is currently serving as the Chief Scientific Officer at Orbital Therapeutics, where they are involved in advancing the use of RNA-based medicines for the treatment of various human diseases. Gilles'srole includes integrating established and emerging technologies and delivery mechanisms to build a transformative portfolio of RNA therapeutics.

Prior to their current position, Gilles was a Scientific Advisory Board Member at Ovensa Inc. and held a Vice President position at Affinivax Inc., where they led the Discovery Research department. At Affinivax Inc., they also served as the Head of Discovery Research. Gilles contributed to the development of innovative research strategies and played a key role in advancing vaccine development and immunomodulation.

Before joining Affinivax Inc., Gilles gained valuable experience at Moderna Therapeutics, where they held the positions of Sr. Director and Director of Immunology. Throughout their tenure, they contributed to the development of immunology strategies, leveraging state-of-the-art technologies to enhance therapeutic approaches.

Gilles also has experience in managing research operations and leading immunology projects at In-Cell-Art. Gilles served as the R&D Operations Manager and later became the Head of Immunology. Gilles'scontributions in this role included overseeing research activities and implementing immunology protocols.

Additionally, Gilles has worked as a Postdoctoral Fellow at the Clinical Research Center, conducting research in various immunology projects. Gilles also served as a Project Leader in Molecular Biology at Vitamfero and held a Post-Doctoral position in Immunology at INRS-Institut Armand-Frappier.

Overall, Gilles Besin has an extensive background in scientific research and development, with a focus on immunology and the integration of novel technologies. Gilles'sexperience spans across various organizations and roles, contributing to the advancement of RNA therapeutics, vaccine development, and immunomodulation.

Gilles BESIN's education history includes a Doctor of Philosophy (Ph.D.) degree in Immunology, which was obtained from the Max Planck Institute for Immunobiology in Germany. Gilles studied at the institute from 2001 to 2006. Before that, they earned an Engineer's degree in Biotechnology from ESBS, where they studied from 1998 to 2001.

In addition to their formal education, Gilles BESIN obtained a certification in "Conflicts of Interest" from the CITI Program in October 2021.